CRISPR THERAPEUTICS AG
(NASDAQ: CRSP)

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

43.300

+3.680 (+9.29%)
Range 38.280 - 39.720   (3.76%)
Open 40.600
Previous Close 39.620
Bid Price 67.000
Bid Volume 8
Ask Price 67.410
Ask Volume 10
Volume 4,175,439
Value -
Remark
Delayed prices. Updated at 13 Feb 2025 05:00.
Data powered by
View All Events


Loading Chart...

Please login to view stock data and analysis